Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis

Melanoma outcomes improved by dual immunotherapy before surgery rather than after

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive mCRPC following docetaxel

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Monitoring ovarian function in oncology studies

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM